Latest From AliveCor Inc.
AliveCor wins US FDA permission to use its mobile ECG to detect heart problems caused by drugs to treat COVID-19 patients.
Medtech Insight features its shortlist of top innovators who showcased their products at the recent Exponential Medicine conference in San Diego.
The latest Apple Watch includes an electrocardiogram that has received de novo clearance from US FDA to detect irregular heart rhythms. The approval, say two top US FDA regulators, is a signal to the digital health industry that the agency is trying to help them innovate.
Atrial fibrillation is always a hot topic at cardiology conferences and this year's European Society of Cardiology Congress in Barcelona was no exception. The meeting highlighted data from a spate of key clinical studies providing more insight into this heart condition, including the CASTLE-AF and CAPTAF studies, which further affirmed the benefits of catheter ablation. Outcomes were also reported from REHEARSE-AF and AFFIRM.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AliveCor Inc.
- Senior Management
Priya Abani, CEO
Jacqueline Shreibati, MD, CMO
- Contact Info
Phone: (855) 338-8800
140 Geary St.
San Francisco, CA 94108
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.